The Top 5 Biosimilar Articles for the Week of January 24

Here are the top 5 biosimilar articles for the week of January 24, 2022.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of January 24, 2022.

Number 5: The International Generic and Biosimilar Medicines Association has appointed a veteran member, Vivian Frittelli, MBA, ACIS, to take over as chair.

Number 4: Insulin costs increased dramatically in recent years, and study authors noted that high costs resulted in nonadherence or insulin rationing for many patients, leading to diabetic complications and even death.

Number 3: A retrospective study characterized the real-world use of a bevacizumab biosimilar (Mvasi) for metastatic colorectal cancer (mCRC) during the first year after it entered the market in the United States.

Number 2: Biosimilars revenues grew by 28% year over year for Biocon Biologics Ltd in the third quarter, which ended December 31, 2021, and is up 32% quarter over quarter.

Number 1: A bevacizumab biosimilar developed by Boehringer Ingelheim has comparable safety, efficacy, immunogenicity, and pharmacokinetics to the reference product in patients with recurrent or metastatic non-small cell lung cancer (NSCLC), according to a new study.

To read all of these articles and more, visit